Shares of Gilead Sciences Inc. (GILD) tumbled over 10% in intraday trading Monday after reporting that a late-stage study of its experiment🎶al lung cancer drug, Trodelvy, missed trial goals.

The company said that a Phase 3 trial of the medication “did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).”

Gilead compared Trodelvy with another cancer-fighting medicine, docetaxel, and noted that while some improvement favoring Trodelvy was observed in those taking it, the difference wasn't significant.

However, Gilead Chief Medical O🔥fficer Merdad Parsey said that the totality of the data “gives us continued confidence in Trodelvy’s 🦩potential in metastatic NSCLC, and in our broader lung cancer clinical development program.”

The company said it would be discussing the results of the trial with 🐲regulators. 

Trodelvy has already received 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) approval to treat several forms of breast and urothelial cancers. It’s one of the company’s best-selling drugs, with sales soaring 58% year-over-year to $283 million in the third quarter.

The news sen🍨t shares of Gilead Sciences down 10.9% to $77.73 per share as of about 3:30 p.m. ET Monday, and into negative territory over the past year.